LPCN 2203
Alternative Names: LPCN-2203Latest Information Update: 25 Mar 2024
At a glance
- Originator Lipocine
- Class Antiepileptic drugs
- Mechanism of Action GABA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Essential tremor
Most Recent Events
- 12 Mar 2024 Lipocine plans to submit a protocol for a proof-of-concept phase-II trial for Essential tremor in the first half of 2024
- 31 Dec 2023 Lipocine completes phase-I trial in Essential tremor (In volunteers) (PO) before December 2023
- 31 Dec 2023 Lipocine plans phase-II trial for Essential tremor (PO) in